Combination of a prostaglandin receptor agonist and an mc1r receptor agonist for the treatment and/or prevention of pigmentation disorders
AssigneeGalderma Research & Development
InventorsPhilippe Martel, Itaru Suzuki, Johannes Voegel, Philippe Andres, Sandrine Rethore
Life of this patent
Estimating the term…
Abstract
A combination of compounds is described for the treatment and/or prevention of skin conditions linked to hypopigmentation. Also described, is a combination product that includes at least one prostaglandin receptor agonist and at least one MC1R receptor agonist, as a medicament for use simultaneously, separately or spread out over time for the treatment and/or prevention of skin conditions linked to hypopigmentation, such as vitiligo.
Claims21
A combination product comprising at least one prostaglandin receptor agonist and at least one MC1R receptor agonist, as a medicament for use simultaneously, separately or spread out over time for the treatment of dermatological conditions linked to hypopigmentation.
The product as claimed in claim in 1, wherein the prostaglandin receptor agonist and the MC1R receptor agonist are present separately from one another in distinct compositions.
An MC1R receptor agonist for use in the treatment of dermatological conditions linked to hypopigmentation, in association or in combination with at least one prostaglandin receptor agonist, as a medicament for use simultaneously, separately or spread out over time.
A composition comprising at least one MC1R receptor agonist and at least one prostaglandin receptor agonist, in a physiologically acceptable carrier.
Dependencies are inferred from the claim text.